氨磺必利
參考文獻

1 2 3  Rosenzweig, P.; Canal, M.; Patat, A.; Bergougnan, L.; Zieleniuk, I.; Bianchetti, G. . Human Psychopharmacology: Clinical and Experimental. 2002-01, 17 (1): 1–13  [2021-10-06]. ISSN 0885-6222. PMID 12404702. doi:10.1002/hup.320. （原始内容存档于2021-10-06） （英语）.
1 2 3 4   (PDF). TGA eBusiness Services. Sanofi-Aventis Australia Pty Ltd. 9 September 2013  [17 October 2013]. （原始内容存档于2019-12-31）.
↑  Caccia, S. . Clinical Pharmacokinetics. May 2000, 38 (5): 393–414. PMID 10843459. doi:10.2165/00003088-200038050-00002.
↑  Noble, Stuart; Benfield, Paul. . CNS Drugs. 1999, 12 (6): 471–483. ISSN 1172-7047. doi:10.2165/00023210-199912060-00005 （英语）.
1 2  Pani, L; Gessa, G L. . Molecular Psychiatry. 2002-03, 7 (3): 247–253  [2021-10-06]. ISSN 1359-4184. PMID 11920152. doi:10.1038/sj.mp.4001040. （原始内容存档于2021-12-27） （英语）.
↑  Pharmaceutical Society of Australia. . Adelaide, S. Aust.: Australian Medicines Handbook. 2013  [2021-10-06]. ISBN 978-0-9805790-9-3. OCLC 826673635. （原始内容存档于2021-10-06）.
1 2 3 4 5  Leucht, Stefan; Cipriani, Andrea; Spineli, Loukia; Mavridis, Dimitris; Örey, Deniz; Richter, Franziska; Samara, Myrto; Barbui, Corrado; Engel, Rolf R. . The Lancet. 2013-09-14, 382 (9896): 951–962  [2021-10-06]. ISSN 0140-6736. doi:10.1016/S0140-6736(13)60733-3. （原始内容存档于2014-10-23） （英语）.
↑  Brayfield, A, ed. (June 2017). "Amisulpride: Martindale: The Complete Drug Reference" （页面存档备份，存于）. MedicineComplete. Pharmaceutical Press. Retrieved 5 August 2017.
↑  Komossa, K; Rummel-Kluge, C; Hunger, H; Schmid, F; Schwarz, S; Silveira da Mota Neto, JI; Kissling, W; Leucht, S (January 2010). "Amisulpride versus other atypical antipsychotics for schizophrenia" （页面存档备份，存于）. The Cochrane Database of Systematic Reviews (1): CD006624. doi:10.1002/14651858.CD006624.pub2. PMC 4164462 （页面存档备份，存于）. PMID 20091599 （页面存档备份，存于）.
↑  Leucht, S; Corves, C; Arbter, D; Engel, RR; Li, C; Davis, JM (January 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis". Lancet. 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842 （页面存档备份，存于）.
↑  Solanki, RK; Sing, P; Munshi, D (Oct–Dec 2009). "Current perspectives in the treatment of resistant schizophrenia". Indian Journal of Psychiatry. 51 (4): 254–60. doi:10.4103/0019-5545.58289. PMC 2802371. PMID 20048449 （页面存档备份，存于）.
↑  Mouaffak, F; Tranulis, C; Gourevitch, R; Poirier, MF; Douki, S; Olié, JP; Lôo, H; Gourion, D (2006). "Augmentation Strategies of Clozapine With Antipsychotics in the Treatment of Ultraresistant Schizophrenia". Clinical Neuropharmacology. 29 (1): 28–33. doi:10.1097/00002826-200601000-00009. PMID 16518132 （页面存档备份，存于）.
↑  Nuss, P.; Hummer, M.; Tessier, C. (2007). "The use of amisulpride in the treatment of acute psychosis" （页面存档备份，存于）. Therapeutics and Clinical Risk Management. 3 (1): 3–11. doi:10.2147/tcrm.2007.3.1.3. PMC 1936283 （页面存档备份，存于）. PMID 18360610 （页面存档备份，存于）.
↑  Vishal Chhabra, Manjeet Singh Bhatia. "Amisulpride: a Brief Review" （页面存档备份，存于）(PDF) DELHI PSYCHIATRY JOURNAL Vol.10 No.2. OCTOBER 2007
↑  Ravizza L. "Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators" （页面存档备份，存于）.  Journal of Psychopharmacology. 13(3):248-54 · February 1999. PMID: 10512080 （页面存档备份，存于）
↑  Smeraldi, E. "Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study" （页面存档备份，存于）. Journal of Affective Disorders, Volume 48, Issue 1, 1998, Pages 47-56, ISSN 0165-0327 （页面存档备份，存于）.
↑  Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O: Amisulpride versus Amineptine and Placebo for the Treatment of Dysthymia （页面存档备份，存于）. Neuropsychobiology 1999;39:25-32. doi: 10.1159/000026556 （页面存档备份，存于）
↑  Lecrubier, Y; Boyer, P; Turjanski, S; Rein, W. . Journal of Affective Disorders. 1997-04, 43 (2): 95–103  [2018-10-24]. ISSN 0165-0327. doi:10.1016/s0165-0327(96)00103-6. （原始内容存档于2018-10-24）.
↑  Carolina, Hardoy Maria; Giovanni, Carta Mauro. . Clinical Practice & Epidemiology in Mental Health. 2010-01-27, 6 (1): 1–3  [2018-10-24]. ISSN 1745-0179. PMID 20498696. doi:10.2174/1745017901006010001. （原始内容存档于2018-10-24）.
↑  Kaul, Vijay; Dutta, Shakti B.; Beg, Mirza A.; Bawa, Shalu; Anjoom, Mohammed; Singh, Nand K.; Dutta, Srihari. . International Journal of Basic & Clinical Pharmacology. 2017-01-21, 4 (2): 349–353  [2018-10-24]. ISSN 2279-0780. doi:10.5455/2319-2003.ijbcp20150438. （原始内容存档于2018-06-14） （英语）.
↑  Sandoz Limited Summary of Product Characteristics, archived from the original on 2014-08-17, retrieved 2014-08-17
1 2 3  "PRODUCT INFORMATION SOLIAN® TABLETS and SOLUTION" （页面存档备份，存于） (PDF). TGA eBusiness Services. Sanofi-Aventis Australia Pty Ltd. 9 September 2013. Retrieved 17 October 2013.
1 2  Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Sep 19]. Greenwood Village, CO: Thomsen Healthcare; 2013.
1 2  Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
1 2  Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
↑  Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics（英语：） (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
↑  McKeage, K; Plosker, GL (2004). "Amisulpride: a review of its use in the management of schizophrenia". CNS Drugs. 18 (13): 933–956. doi:10.2165/00023210-200418130-00007. ISSN 1172-7047 （页面存档备份，存于）. PMID 15521794 （页面存档备份，存于）.
↑  Natesan, S; Reckless, GE; Barlow, KB; Nobrega, JN; Kapur, S (October 2008). "Amisulpride the 'atypical' atypical antipsychotic — Comparison to haloperidol, risperidone and clozapine". Schizophrenia Research. 105 (1–3): 224–235. doi:10.1016/j.schres.2008.07.005. PMID 18710798 （页面存档备份，存于）.
↑  Isbister, GK; Balit, CR; Macleod, D; Duffull, SB (August 2010). "Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes". Journal of Clinical Psychopharmacology. 30 (4): 391–395. doi:10.1097/JCP.0b013e3181e5c14c. PMID 20531221 （页面存档备份，存于）.
↑  Joy, JP; Coulter, CV; Duffull, SB; Isbister, GK (August 2011). "Prediction of Torsade de Pointes From the QT Interval: Analysis of a Case Series of Amisulpride Overdoses". Clinical Pharmacology & Therapeutics. 90 (2): 243–245. doi:10.1038/clpt.2011.107. PMID 21716272 （页面存档备份，存于）.
1 2 3  Taylor, D; Paton, C; Shitij, K (2012). Maudsley Prescribing Guidelines in Psychiatry (11th ed.). West Sussex: Wiley-Blackwell. ISBN 978-0-47-097948-8.
↑  Levine, M; Ruha, AM (July 2012). "Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management". CNS Drugs. 26 (7): 601–611. doi:10.2165/11631640-000000000-00000. PMID 22668123 （页面存档备份，存于）.
↑  Roth, BL; Driscol, J. "PDSP Ki Database" （页面存档备份，存于）. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47  Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009). "Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo" （页面存档备份，存于）. Psychopharmacology. 205 (1): 119–28. doi:10.1007/s00213-009-1521-8. PMC 2821721 （页面存档备份，存于）. PMID 19337725 （页面存档备份，存于）.
1 2  Maitre, M.; Ratomponirina, C.; Gobaille, S.; Hodé, Y.; Hechler, V. (Apr 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". European Journal of Pharmacology. 256 (2): 211–214. doi:10.1016/0014-2999(94)90248-8. PMID 7914168 （页面存档备份，存于）.
↑  Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997). "Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity". J. Pharmacol. Exp. Ther. 280(1): 83–97. PMID 8996185 （页面存档备份，存于）.
↑  Cassano, G. B.a; Jori, M. C.b. "Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study" （页面存档备份，存于）. International Clinical Psychopharmacology: January 2002 - Volume 17 - Issue 1 - p 27-32
↑  Blomme, Audrey; Conraux, Laurence; Poirier, Philippe; Olivier, Anne; Koenig, Jean-Jacques; Sevrin, Mireille; Durant, François; George, Pascal (2000), "Amisulpride, Sultopride and Sulpiride: Comparison of Conformational and Physico-Chemical Properties" （页面存档备份，存于）, Molecular Modeling and Prediction of Bioactivity, Springer US, pp. 404–405, doi:10.1007/978-1-4615-4141-7_97, ISBN 9781461368571, retrieved 2018-09-21
↑  Lecrubier, Y.; et al. (2001). "Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia". Neuropsychobiology. 44 (1): 41–46. doi:10.1159/000054913. PMID 11408792 （页面存档备份，存于）.
↑  Kaplan, A. (2004). "Psychotropic Medications Around the World". Psychiatric Times. 21 (5).